Navigation Links
Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Date:8/27/2013

nalysis and without the clinical study report for the interim analysis; the potential to accelerate the timing of the review of the Contrave NDA; the safety and effectiveness of Contrave; the potential for past Contrave clinical trials to predict the outcome of future Contrave clinical trials; the SPA and the protocol for the Contrave® cardiovascular outcomes trial, or Light Study; the potential for and timing of a submission of an MAA in the European Union; the potential for approval of the Contrave MAA by the EMA; and the potential to license commercial rights to Contrave outside North America. The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit‐risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for th
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. Fate Therapeutics Strengthens Its iPSC Platform
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Telbec/ - Mirego, leader in mobile strategies and solutions, is ... app extensions for the all new Apple Watch. Made in ... and MediaMiser, these extensions will reinvent the way users receive ... wrist use.  Available today in ... tactile smartwatch that makes for an excellent buddy for business, ...
(Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
(Date:4/23/2015)... Mount Dora, Florida (PRWEB) April 23, 2015 ... announced that it intends to conduct a groundbreaking ... can begin to be reversed in as little ... researchers—using the science of metabolic and nutritional medicine—will ... conditions that cripple and destroy our aging brain. ...
(Date:4/23/2015)... 2015 Six startups from Russia ... 4-17 as part of the U.S.-Russia Innovation Corridor ... of biotechnology startups to participate in the program ... and the University of Maryland (UMD) signed a ... respective universities in the biomedical industry in 2013. ...
Breaking Biology Technology:Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4
... 20 Humanitarian, Dr. Gary Michelson,is "making an ... Gilbreath, Executive Director of Found Animals Foundation (Found,Animals) ... Found Animals and its strategic partner the Alliance ... launch of The Michelson Prize in,Reproductive Biology at ...
... The Board of Directors,of Eli Lilly and Company ... as a,new member, effective December 1, 2008. Oberhelman, 55, ... is a member of Caterpillar,s,executive office. As a member ... audit committee and finance committee. He will stand for,election ...
... ORANGE COUNTY, Calif., Oct. 20 Beckman,Coulter, Inc. ... Board of Directors,declared a quarterly dividend payout of ... payable on November 17, 2008 to all,stockholders of ... the 78th,consecutive, quarterly payout of dividends., (Logo: ...
Cached Biology Technology:Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 2Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 3Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 4Douglas Oberhelman Elected to Lilly Board of Directors 2Douglas Oberhelman Elected to Lilly Board of Directors 3
(Date:3/24/2015)... ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of the ... report to their offering. This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Biometrics - Global Strategic Business Report" report to their ... Iris Biometrics in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Latin America . Annual ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... found that pre-existing malaria prevents secondary infection by another ... iron availability in the liver of the host. This ... Nature Medicine and has important implications for ... affects millions of individuals worldwide. The study was ...
... a class of compounds that could be a boon to ... study, published online in Nature Chemical Biology on ... and selectively block the activity of a large and diverse ... hydrolase-blocking compounds have been turned into drugs to treat obesity, ...
... May 15, 2011) An international research team ... Institute for Breast Cancer Research at Princess Margaret Hospital ... the process whereby tumour cells adapt and survive under ... published today in Genes and Development ( ...
Cached Biology News:Malaria against malaria: A pre-existing malaria infection can prevent a second infection 2Malaria against malaria: A pre-existing malaria infection can prevent a second infection 3Scientists find new class of compounds with great potential for research and drug development 2Scientists find new class of compounds with great potential for research and drug development 3Cancer scientists discover new way breast cancer cells adapt to environmental stress 2
...
Chicken anti-EEA1...
... Cell Dissociation Buffers are membrane-filtered ... salts chelating agents and cell-conditioning agents ... balanced salt solution or Ca2+- ... dissociation of mammalian cells from support ...
Request Info...
Biology Products: